A Tetraphase Pharmaceuticals antibiotic has earned FDA approval, adding a new treatment to the effort to address drug-resistant infections.
The FDA decision for the Tetraphase (NASDAQ: TTPH) drug, eravacycline (Xerava), covers complicated intra-abdominal infections (cIAI) in adults. It’s the first drug approval for the Watertown, MA-based drug developer, and shares of the company rose 5.5 percent in after-hours trading Monday.
Gut infections can become complicated when they spread, due to a tear or other damage in the gastrointestinal tract. In two Phase 3 studies, Tetraphase tested a twice-daily infusion of its drug against ertapenem (Invanz), a now off-patent antibiotic… Read more »
UNDERWRITERS AND PARTNERS